LSG Lawsuit Status Guide
Menu
Active / Investigating

Ozempic Lawsuit in Illinois (GLP-1 Claims)

Information for Illinois residents researching Ozempic and GLP-1 lawsuits: gastroparesis and bowel-injury allegations, MDL-3094 status, eligibility factors, records, and Illinois filing deadlines.

This guide is for general information only. It does not provide legal advice, does not create an attorney-client relationship, and case status can change.

Illinois Defective Drug Updated June 11, 2026
Back to Ozempic / GLP-1 guide

Frequently Asked Questions

What is the Ozempic lawsuit in Illinois about?

Lawsuits allege GLP-1 medications such as Ozempic can cause gastroparesis, ileus, and bowel obstruction, and that warnings were inadequate. Illinois residents' cases are generally transferred into federal MDL-3094 for coordinated proceedings. Defendants dispute the allegations.

Can a Illinois resident join the Ozempic MDL?

Possibly. Cases filed by Illinois residents in federal court are routinely transferred into MDL-3094 in the Eastern District of Pennsylvania. Whether an individual claim is filed there depends on case strategy and individual facts.

What is the Ozempic lawsuit statute of limitations in Illinois?

Illinois's general personal injury period is 2 years (735 ILCS 5/13-202), and illinois courts apply a discovery rule in many injury cases, so the clock may run from when the injury and its likely cause were or should have been discovered. Only a lawyer can confirm the deadline for a specific situation.

Which drugs are included for Illinois claimants?

Filed cases involve Ozempic, Wegovy, Rybelsus, and Saxenda (Novo Nordisk) and Mounjaro, Zepbound, and Trulicity (Eli Lilly). Both diabetes and weight-loss prescriptions appear among filed cases.

What records matter most for a Illinois claim?

Prescription and pharmacy records, gastroenterology records, gastric emptying study results, hospitalization records, and imaging or endoscopy reports are commonly requested first.

Has there been an Ozempic settlement?

No. As of June 2026 no settlement program exists in the GLP-1 litigation. The Rule 702 hearings set for September 10-18, 2026 and the rulings that follow are the next events expected to shape settlement posture. Bellwether trial dates have not been set, and no outcome is guaranteed.

Is Ozempic recalled?

No. GLP-1 medications remain FDA-approved and on the market. The litigation concerns warnings and alleged injuries, not availability. Medication decisions belong with a licensed healthcare professional.

Does this page provide legal advice?

No. This page is general legal information for research purposes only and does not create an attorney-client relationship.

Other Lawsuit Guides in Illinois

Sources and Update Log

Last reviewed
June 11, 2026
Last updated
June 11, 2026

Sources reviewed may include court filings, MDL notices, public agency materials, manufacturer disclosures, and law firm case-status updates where applicable.

Recent updates focus on lawsuit status, state-specific context, eligibility factors, records, deadlines, and editorial disclosures.